Key points are not available for this paper at this time.
This integrative review examines the differential expression of miRNAs in breast cancer patients across various disease stages. Through analysis of 42 articles published between 2005 and 2023, the review identifies multiple miRNAs with significant diagnostic, prognostic, and predictive potential in breast cancer management. These small noncoding RNAs, accessible through liquid biopsy, demonstrate notable potential for early detection, molecular subtype classification, treatment response prediction, and relapse monitoring. The findings highlight miRNAs as promising biomarkers for precision medicine approaches, potentially enhancing clinical decision-making and improving patient outcomes. Notably, miRNAs such as miR-21, miR-155, and members of the miR-200 family show consistent associations with clinical parameters across multiple studies. The accessibility of miRNAs in blood and other body fluids, combined with their stability and specificity, positions them as valuable tools that could complement conventional diagnostic methods and support more personalized treatment strategies in breast cancer care.
Silva et al. (Sun,) studied this question.